Sanofi shutters Kiadis biotech three years after €308M buyout

2024-04-10

临床1期并购临床2期免疫疗法细胞疗法

Sanofi has confirmed plans to close down Kiadis Pharma, three years after it acquired the Dutch biotech and its allogeneic NK cell technology platform for €308 million ($331 million).

"Despite exhaustive efforts to explore potential divestment options, including sale, we are proposing to close the legacy Kiadis business," a Sanofi spokesperson said in an emailed statement to FirstWord. "This proposal was made after careful consideration of various factors, including market conditions and strategic priorities."

Sanofi had heralded the acquisition saying Kiadis' NK cell technology platform would have "broad application against liquid and solid tumours, and create synergies with Sanofi's emerging immuno-oncology pipeline."

The French drugmaker's pipeline lists one clinical-stage NK programme from Kiadis, SAR445419, a product derived from universal donor NK cells and in early-stage development up until recently. An April 8 update on ClinicalTrials.gov lists the recruitment status of a Phase I study in acute myeloid leukaemia (AML) as "terminated" due to "divestment of Kiadis."

Meanwhile, a Phase II study of the treatment in patients with high-risk myeloid malignancies undergoing stem-cell transplant was "cancelled" by the sponsor, but the move was "not related to safety concern," according to a March 5 update on the ClinicalTrials.gov site.

Last year, Sanofi's global head of business development Michael Palladinetti told FirstWord that the company was particularly focused on harnessing NK cells to treat cancer, citing a spate of deals it had signed in that domain such as with Scribe Therapeutics and Innate Pharma. See – ViewPoints: An inside look at Sanofi's BD strategy.

However, the choice to shut down Kiadis aligns with Sanofi's planned shift in pipeline priorities. CEO Paul Hudson hinted at the JP Morgan Healthcare conference earlier this year that while Sanofi seeks to become the industry's leading immunology player, it planned to deprioritise oncology as an area of focus. "We are not out of oncology, but our bets are much earlier and that’s changed the tonality because it's a huge consumer of investment in R&D," he said at the time.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构